Lanatoside C

Lanatoside C (CAS No.: 17575-22-3) is a plant derived cardiac glycoside widely used as a bioactive small molecule tool in cardiovascular pharmacology, virology, and oncology focused discovery research, where it is commonly categorized as a Na and K ATPase modulating natural product scaffold with pleiotropic downstream effects on cellular signaling and stress responses; in mechanistic studies it has been associated with regulation of MAPK, Wnt, JAK STAT, and PI3K AKT mTOR pathway activity, together with induction of G2 M cell cycle arrest, autophagy, and apoptosis related phenotypes in susceptible cell systems, supporting its use for pathway interrogation and hypothesis driven target validation in disease relevant models; reported in vitro antiviral and antiproliferative activities are generally observed from nanomolar to micromolar ranges, including submicromolar inhibition in selected virus infection assays such as HuH 7 based dengue models, while broader screening literature describes activity against multiple RNA virus groups and diverse tumor cell contexts at low micromolar levels depending on assay format and endpoint definition; accordingly, Lanatoside C is frequently applied in phenotypic screening, mechanism of action studies, resistance biology experiments, and combination design workflows across cell based platforms and exploratory animal research, with the concentrations or doses used in experiments typically depending on specific experimental designs and research objectives, and all use is restricted to controlled laboratory research settings rather than any human use, clinical application, food related use, or consumer product purpose.